Liliana Montoya, MD
Neurology · Port Charlotte, FLNPI 1245255793
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,645 of the $12,342 with a category attached, or 78.1%. 57 manufacturers reported payments, led by Biogen at 26.4% of the total. Reporting peaked in 2022 at $3,731 and has fallen 53.6% since, to $1,730 in 2025.
Across 451 payments — averaging $27.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$3K
- AbbVie$1K
- Novartis$833
- Lilly USA, LLC$582
- EMD Serono, Inc.$561
- Amgen$497
- plus $6K from 51 others
Across 455 payments — averaging $7455.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.5M
- Eisai Inc.$309K
- Adamas Pharmaceuticals, Inc.$294K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$83K
- Regeneron$76K
- EMD Serono, Inc.$63K
- plus $113K from 9 others
What the payments were for
- Consulting fees$2,41820%
- Speaking & faculty fees$470%
- Food & beverage$9,64578%
- Education$2332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,342 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RebifInterferon Beta-1a/Albumin | 17 | $261,436 |
| AustedoDeutetrabenazine | 19 | $225,454 |
| VumerityDiroximel Fumarate | 24 | $208,680 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 13 | $128,028 |
| Kesimpta PenOfatumumab | 11 | $111,658 |
| Nurtec OdtRimegepant Sulfate | 62 | $104,949 |
| NuplazidPimavanserin Tartrate | 14 | $98,482 |
| RytaryCarbidopa/Levodopa | 62 | $79,075 |
| AptiomEslicarbazepine Acetate | 12 | $58,771 |
| Aimovig AutoinjectorErenumab-Aooe | 53 | $48,640 |
| UbrelvyUbrogepant | 13 | $41,874 |
| Emgality PenGalcanezumab-Gnlm | 45 | $41,160 |
| RexultiBrexpiprazole | 12 | $25,184 |
| Dalfampridine ErDalfampridine | 23 | $24,438 |
| BotoxOnabotulinumtoxina | 15 | $19,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Rebif | $561 | $261,43617 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $295 | $225,45419 claims |
| BiogenVumerity | $3,259 | $208,68024 claims |
| PfizerNurtec Odt, Eliquis | $226 | $111,23273 claims |
| Acadia Pharmaceuticals IncNuplazid | $145 | $98,48214 claims |
| AbbVieUbrelvy, Botox, Qulipta, Namzaric | $1,046 | $92,84460 claims |
| Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil | $360 | $81,85184 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $203 | $25,18412 claims |
| Eisai Inc.Fycompa | $493 | $13,72912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.
Other neurology in Port Charlotte
- Ramon GilPort Charlotte$663K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.